

UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Tally

Meeting Date: June 8, 2023
 Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/Recommendation	Vote
Meeting called to order	G. Shutzberg	5:02 PM EST		
A. Minutes from previous meetings	G. Shutzberg	Review of Minutes from March 9, 2023	Minutes reviewed, approved	Yes
B. Formulary Review - New	C. Lichtinger	Cuvrior		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
	C. Lichtinger	Jaypirca		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
	M. Reisman	Krazati		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
	M. Reisman	Orserdu		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
	M. Reisman	Rezlidhia		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
C. Formulary Review - PDL Modifications	C. Lichtinger	Confirm Review of PDL Modifications Grid	Yes/No	Yes
		Recommendation: • Rezvoglar Pen : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Recommendation: • Lantus/Lantus Solostar : Move to preferred across all applicable lines of business on 11/1/2023	Motion made, seconded, and carried to accept recommendation	8:0
		Recommendation: • Insulin Lispro vial : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Recommendation: • tinidazole tablet : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Recommendation: • Wixela Inhub : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Recommendation: • fluticasone-salmeterol diskus (generic Advair Diskus) : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Recommendation: • atovaquone-proguanil tablet : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Recommendation: • Invokana tablet : Move to non-preferred with PA in the NY EPP market	Motion made, seconded, and carried to accept recommendation	8:0
		Recommendation: • SymlinPen injection : Move to non-preferred with PA across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Recommendation: • lurasidone tablet, aripiprazole tablet, chlorpromazine tablet, clozapine tablet, haloperidol tablet, haloperidol decanoate IM solution, fluphenazine oral concentrate/elixir/tablet/ injection, fluphenazine decanoate injection, loxapine capsule, olanzapine tablet, perphenazine tablet, quetiapine tablet, risperidone tablet/solution, thioridazine tablet, thiothixene capsule, trifluoperazine tablet, ziprasidone capsule : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Recommendation: • clozapine 200mg tablet : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Recommendation: • quetiapine 150mg tablet : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Recommendation: • quetiapine extended-release tablet : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Recommendation: • clomipramine capsule : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Recommendation: • dalfampridine extended-release tablet : Move to preferred with DX2RX across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0

D. Formulary Review - New Drugs- Medical	C. Lichtinger	Confirm Review of New Drugs- Medical Grid	Yes/No	Yes
		Hemgenix Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Rebyota Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Tzield Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Legembi Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Lunsumio Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Sezaby Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Briumvi Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Sunlenca Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Altuviio Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
		Trodelvy Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	8:0
E. Formulary Review - Drugs Evaluated Per Grid	C. Lichtinger	Apply recommendations as outlined in grid	Motion made, seconded, and carried to accept recommendation	8:0
F. Clinical Guidelines	C. Lichtinger	Clinical Guideline Review		
		Apply New Pharmacy Guidelines	Motion made, seconded, and carried to accept recommendation	8:0
		Continue to Apply Pharmacy Guidelines Requiring Modifications	Motion made, seconded, and carried to accept recommendation	8:0
		Remove Pharmacy Guidelines Requiring Archival	Motion made, seconded, and carried to accept recommendation	8:0
G. Quality Monitoring	L. Charlton/ M. Reisman	Confirm Review of Quality Data	Yes/No	Yes
	L. Charlton	DUR Review		
	M. Reisman	Drug Recalls – 1st Quarter 2023		
	M. Reisman	Top 25 Drugs by Spend and Volume – 1st Quarter 2023		
	M. Reisman	Top 10 Drugs Requested - Approvals and Denials – 1st Quarter 2023		
	M. Reisman	Grievances and Appeals Data – 1st Quarter 2023		
	M. Reisman	Inter-Rater Reliability (IRR) – 1st Quarter 2023 • Pharmacists		
H. Hot Topic	Clayton Stehr	Redeterminations Overview		
	Comment:	Joyce Kossol asked is there something we can do to get the word out in the independent pharmacy market, maybe through the PA Pharmacy Association? Clayton will connect with Joyce offline.		
Adjournment	G. Shutzberg	6:30 PM EST		

Respectfully Submitted to the Committee,



James P. Hancovsky, M.S.I.A., R.Ph.
Chief Pharmacy Officer, UHC C&S